Beacon Pointe Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $338K | Buy |
1,036
+169
| +19% | +$55.1K | ﹤0.01% | 988 |
|
|
2025
Q1 | $234K | Sell |
867
-68
| -7% | -$18.4K | ﹤0.01% | 1087 |
|
|
2024
Q4 | $220K | Sell |
935
-440
| -32% | -$104K | ﹤0.01% | 1103 |
|
|
2024
Q3 | $378K | Sell |
1,375
-137
| -9% | -$37.7K | ﹤0.01% | 938 |
|
|
2024
Q2 | $367K | Sell |
1,512
-124
| -8% | -$30.1K | ﹤0.01% | 974 |
|
|
2024
Q1 | $245K | Hold |
1,636
| – | – | ﹤0.01% | 1166 |
|
|
2023
Q4 | $313K | Sell |
1,636
-55
| -3% | -$10.5K | ﹤0.01% | 1050 |
|
|
2023
Q3 | $299K | Buy |
1,691
+111
| +7% | +$19.7K | ﹤0.01% | 1057 |
|
|
2023
Q2 | $300K | Sell |
1,580
-126
| -7% | -$23.9K | ﹤0.01% | 877 |
|
|
2023
Q1 | $342K | Sell |
1,706
-84
| -5% | -$16.8K | 0.01% | 888 |
|
|
2022
Q4 | $425K | Buy |
1,790
+33
| +2% | +$7.84K | 0.01% | 746 |
|
|
2022
Q3 | $351K | Buy |
1,757
+156
| +10% | +$31.2K | 0.01% | 751 |
|
|
2022
Q2 | $235K | Sell |
1,601
-139
| -8% | -$20.4K | 0.01% | 916 |
|
|
2022
Q1 | $284K | Buy |
1,740
+395
| +29% | +$64.5K | ﹤0.01% | 1000 |
|
|
2021
Q4 | $228K | Sell |
1,345
-205
| -13% | -$34.8K | 0.01% | 831 |
|
|
2021
Q3 | $293K | Buy |
+1,550
| New | +$293K | 0.01% | 716 |
|